REFERENCES
1. Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023;20:338-49.
2. Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4:47-53.
3. Kakeji Y, Ishikawa T, Suzuki S, et al. A retrospective 5-year survival analysis of surgically resected gastric cancer cases from the Japanese Gastric Cancer Association nationwide registry (2001-2013). Gastric Cancer. 2022;25:1082-93.
4. Lan Q, Wang P, Tian S, Dong W. Mining TCGA database for genes of prognostic value in gastric cancer microenvironment. J Cell Mol Med. 2020;24:11120-32.
5. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423-37.
6. Xu L, Zou C, Zhang S, et al. Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. J Hematol Oncol. 2022;15:87.
7. Li C, Zhang Z, Peng E, Peng J. Role of an exosomes-related lncRNAs signature in tumor immune microenvironment of gastric cancer. Front Cell Dev Biol. 2022;10:873319.
8. Sui X, Wu G. Immune landscape and prognostic gene signatures in gastric cancer: implications for cachexia and clinical outcomes. Front Immunol. 2023;14:1297363.
9. Miliotis C, Ma Y, Katopodi XL, et al. Determinants of gastric cancer immune escape identified from non-coding immune-landscape quantitative trait loci. Nat Commun. 2024;15:4319.
10. Xu L, Li B, Liu Y, et al. Unveiling KLHL23 as a key immune regulator in hepatocellular carcinoma through integrated analysis. Aging. 2024;16:13608-26.
11. Wu F, Xu L, Tu Y, et al. Sirtuin 7 super-enhancer drives epigenomic reprogramming in hepatocarcinogenesis. Cancer Lett. 2022;525:115-30.
12. Li B, Chen H, Yang S, et al. Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers. Mol Cancer. 2023;22:71.
13. Janjigian YY, Kawazoe A, Yañez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600:727-30.
14. Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402:2197-208.
15. Rha SY, Oh DY, Yañez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1181-95.
16. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27-40.
17. Chao J, Fuchs CS, Shitara K, et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 2021;7:895-902.
18. Galassi C, Chan TA, Vitale I, Galluzzi L. The hallmarks of cancer immune evasion. Cancer Cell. 2024;42:1825-63.
19. Germanà E, Pepe L, Pizzimenti C, et al. Programmed cell death ligand 1 (PD-L1) immunohistochemical expression in advanced urothelial bladder carcinoma: an updated review with clinical and pathological implications. Int J Mol Sci. 2024;25:6750.
20. Russo AE, Strong VE. Gastric cancer etiology and management in Asia and the West. Annu Rev Med. 2019;70:353-67.
21. Peña-Romero AC, Orenes-Piñero E. Dual effect of immune cells within tumour microenvironment: pro- and anti-tumour effects and their triggers. Cancers. 2022;14:1681.
22. Duan S, Wang P, Liu F, et al. Novel immune-risk score of gastric cancer: a molecular prediction model combining the value of immune-risk status and chemosensitivity. Cancer Med. 2019;8:2675-85.
23. Sun P, Lu Q, Li Z, et al. Assessment of prognostic prediction models for gastric cancer using genomic and transcriptomic profiles. Meta Gene. 2021;28:100890.
24. Qiu L, Qu X, He J, et al. Predictive model for risk of gastric cancer using genetic variants from genome-wide association studies and high-evidence meta-analysis. Cancer Med. 2020;9:7310-6.
25. Cheong JH, Wang SC, Park S, et al. Development and validation of a prognostic and predictive 32-gene signature for gastric cancer. Nat Commun. 2022;13:774.
26. Xu X, Lu Y, Wu Y, et al. A signature of seven immune-related genes predicts overall survival in male gastric cancer patients. Cancer Cell Int. 2021;21:117.
27. Jiang B, Sun Q, Tong Y, et al. An immune-related gene signature predicts prognosis of gastric cancer. Medicine. 2019;98:e16273.
28. Li C, Huang Y, Yi X, Tang Y, Okita R, He J. Pan-cancer prognostic model and immune microenvironment analysis of natural killer cell-related genes. Transl Cancer Res. 2024;13:1936-53.
29. Liu Y, Li D, Chen Y, et al. Integrated bioinformatics analysis for conducting a prognostic model and identifying immunotherapeutic targets in gastric cancer. BMC Bioinformatics. 2023;24:191.
30. Molinaro C, Martoriati A, Cailliau K. Proteins from the DNA damage response: regulation, dysfunction, and anticancer strategies. Cancers. 2021;13:3819.
31. Wang M, Chen S, Ao D. Targeting DNA repair pathway in cancer: mechanisms and clinical application. MedComm. 2021;2:654-91.
32. Chen M, Linstra R, van Vugt MATM. Genomic instability, inflammatory signaling and response to cancer immunotherapy. Biochim Biophys Acta Rev Cancer. 2022;1877:188661.
33. Shi C, Qin K, Lin A, et al. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy. J Exp Clin Cancer Res. 2022;41:268.
34. Ye Z, Shi Y, Lees-Miller SP, Tainer JA. Function and molecular mechanism of the DNA damage response in immunity and cancer immunotherapy. Front Immunol. 2021;12:797880.
35. Zhou C, Lin A, Cao M, et al. Activation of the DDR pathway leads to the down-regulation of the TGFβ pathway and a better response to ICIs in patients with metastatic urothelial carcinoma. Front Immunol. 2021;12:634741.
36. Lou S, Wang Y, Zhang J, et al. Patient-level DNA damage repair pathway profiles and anti-tumor immunity for gastric cancer. Front Immunol. 2021;12:806324.
37. Graves EE, Maity A, Le QT. The tumor microenvironment in non-small-cell lung cancer. Semin Radiat Oncol. 2010;20:156-63.
38. Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019;20:840.
39. Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374-403.
40. Sun Y, Liu L, Fu Y, et al. Metabolic reprogramming involves in transition of activated/resting CD4+ memory T cells and prognosis of gastric cancer. Front Immunol. 2023;14:1275461.
41. Wang F, Lau JKC, Yu J. The role of natural killer cell in gastrointestinal cancer: killer or helper. Oncogene. 2021;40:717-30.
42. Li J, Sun J, Zeng Z, et al. Tumour-associated macrophages in gastric cancer: from function and mechanism to application. Clin Transl Med. 2023;13:e1386.
43. Sukri A, Hanafiah A, Kosai NR. The roles of immune cells in gastric cancer: anti-cancer or pro-cancer? Cancers. 2022;14:3922.
